-
Targeting mitochondria: restoring the antitumor efficacy of exhausted T cells Mol. Cancer (IF 27.7) Pub Date : 2024-11-19 Mei-Qi Yang, Shu-Ling Zhang, Li Sun, Le-Tian Huang, Jing Yu, Jie-Hui Zhang, Yuan Tian, Cheng-Bo Han, Jie-Tao Ma
Immune checkpoint blockade therapy has revolutionized cancer treatment, but resistance remains prevalent, often due to dysfunctional tumor-infiltrating lymphocytes. A key contributor to this dysfunction is mitochondrial dysfunction, characterized by defective oxidative phosphorylation, impaired adaptation, and depolarization, which promotes T cell exhaustion and severely compromises antitumor efficacy
-
Stool and blood biomarkers for colorectal cancer management: an update on screening and disease monitoring Mol. Cancer (IF 27.7) Pub Date : 2024-11-19 Alessandro Mannucci, Ajay Goel
Biomarkers have revolutionized the management of colorectal cancer (CRC), facilitating early detection, prevention, personalized treatment, and minimal residual disease (MRD) monitoring. This review explores current CRC screening strategies and emerging biomarker applications. Main body. We summarize the landscape of non-invasive CRC screening and MRD detection strategies, discuss the limitations of
-
Uncovering the predictive and immunomodulatory potential of transient receptor potential melastatin family-related CCNE1 in pan-cancer Mol. Cancer (IF 27.7) Pub Date : 2024-11-18 Nan Zhang, Hao Zhang, Shuyu Li, Wantao Wu, Peng Luo, Zaoqu Liu, Yu Chen, Zhiwei Xia, Chenshen Huang, Quan Cheng
Millions of new cases of cancer are diagnosed worldwide each year, making it a serious public health concern. Developments in customized therapy and early detection have significantly enhanced treatment for and results from cancer. Therefore, it is important to investigate new molecular biomarkers. In this study, we created an efficient transient receptor potential melastatin (TRPM) family members-related
-
Single-cell and spatial transcriptomics identify COL6A3 as a prognostic biomarker in undifferentiated pleomorphic sarcoma Mol. Cancer (IF 27.7) Pub Date : 2024-11-15 Jason C. Klein, Lei Wang, Douglas Strand, Chewlan Lastufka, Gregory A. Hosler, Gary C. Hon
Undifferentiated pleomorphic sarcoma (UPS) and related tumors are the most common type of soft tissue sarcoma. However, this spectrum of tumors has different etiologies with varying rates of metastasis and survival. Two dermal-based neoplasms in this class of pleomorphic sarcomas, atypical fibroxanthoma (AFX) and pleomorphic dermal sarcoma (PDS), are challenging to differentiate at initial biopsy but
-
Clinical advances and challenges in targeting FGF/FGFR signaling in lung cancer Mol. Cancer (IF 27.7) Pub Date : 2024-11-15 Mei Peng, Jun Deng, Xiangping Li
Fibroblast growth factors (FGFs) and their receptors regulate numerous cellular processes, such as metabolism and signal transduction, but can also drive tumorigenesis. Specifically, in lung cancer, the overexpression of FGFs, as well as the amplification, mutation and fusion of FGFR genes, are closely linked to the initiation, progression and resistance of the disease, suggesting that targeting FGF/FGFR
-
Cuproptosis, ferroptosis and PANoptosis in tumor immune microenvironment remodeling and immunotherapy: culprits or new hope Mol. Cancer (IF 27.7) Pub Date : 2024-11-15 Xiaojie Zhang, Bufu Tang, Jinhua Luo, Yang Yang, Qiaoyou Weng, Shiji Fang, Zhongwei Zhao, Jianfei Tu, Minjiang Chen, Jiansong Ji
Normal life requires cell division to produce new cells, but cell death is necessary to maintain balance. Dysregulation of cell death can lead to the survival and proliferation of abnormal cells, promoting tumor development. Unlike apoptosis, necrosis, and autophagy, the newly recognized forms of regulated cell death (RCD) cuproptosis, ferroptosis, and PANoptosis provide novel therapeutic strategies
-
Immune dynamics shaping pre-metastatic and metastatic niches in liver metastases: from molecular mechanisms to therapeutic strategies Mol. Cancer (IF 27.7) Pub Date : 2024-11-14 Chang Zhu, Jing-Yu Liao, Yi-Yang Liu, Ze-Yu Chen, Rui-Zhi Chang, Xiao-Ping Chen, Bi-Xiang Zhang, Jun-Nan Liang
Liver metastases are commonly detected in the advanced stages of various malignant tumors, representing a significant clinical challenge. Throughout the process of liver metastases formation, immune cells play a pivotal role, particularly in the pre-metastatic and metastatic niches within the liver. Immune cells establish extensive and intricate interactions with tumor cells and other components in
-
The PI3K-AKT-mTOR axis persists as a therapeutic dependency in KRASG12D-driven non-small cell lung cancer Mol. Cancer (IF 27.7) Pub Date : 2024-11-12 W. J. McDaid, L. Wilson, H. Adderley, A. Martinez-Lopez, M. J. Baker, J. Searle, L. Ginn, T. Budden, M. Aldea, A. Marinello, J. V. Aredo, A. Viros, B. Besse, H. A. Wakelee, F. Blackhall, S. Castillo-Lluva, C. R. Lindsay, A. Malliri
KRASG12C and KRASG12D inhibitors represent a major translational breakthrough for non-small cell lung cancer (NSCLC) and cancer in general by directly targeting its most mutated oncoprotein. However, resistance to these small molecules has highlighted the need for rational combination partners necessitating a critical understanding of signaling downstream of KRAS mutant isoforms. We contrasted tumor
-
Cellular mechanisms of combining innate immunity activation with PD-1/PD-L1 blockade in treatment of colorectal cancer Mol. Cancer (IF 27.7) Pub Date : 2024-11-12 Qi Xie, Xiaolin Liu, Rengyun Liu, Jingxuan Pan, Jing Liang
PD-1/PD-L1 blockade therapies have displayed extraordinary clinical efficacy for melanoma, renal, bladder and lung cancer; however, only a minority of colorectal cancer (CRC) patients benefit from these treatments. The efficacy of PD-1/PD-L1 blockade in CRC is limited by the complexities of tumor microenvironment. PD-1/PD-L1 blockade immunotherapy is based on T cell-centered view of tumor immunity
-
Regulatory T cells in immune checkpoint blockade antitumor therapy Mol. Cancer (IF 27.7) Pub Date : 2024-11-08 An Zhang, Tao Fan, Yixiao Liu, Guanhua Yu, Chunxiang Li, Zheng Jiang
Regulatory T cells (Tregs), an essential component of the human immune system, are a heterogeneous group of T lymphocytes with the ability to suppress immune responses and maintain immune homeostasis. Recent evidence indicates that Tregs may impair antitumor immunity and facilitate cancer progression by weakening functions of effector T cells (Teffs). Consequently, targeting Tregs to eliminate them
-
Traditional Chinese medicine in treating upper digestive tract cancers Mol. Cancer (IF 27.7) Pub Date : 2024-11-08 Alexis Shiying Huang, Jiaying Wu, Aftab AMIN, Xiu-Qiong Fu, Zhi-Ling Yu
Upper digestive tract cancers, such as oral cavity, laryngeal, esophageal, and gastric cancers, account for 10% of cancer cases and 14.5% of cancer-related deaths worldwide. Conventional treatments often provide limited survival benefits and are frequently associated with adverse effects and drug resistance. Chinese herbal drugs (CHDs) are widely used in the Far East for managing these cancers. In
-
Variability in non-tumor areas of colorectal cancer patients as revealed by endoscopic intestinal step biopsies Mol. Cancer (IF 27.7) Pub Date : 2024-11-07 Shoko Ikuta, Yutaka Saito, So Takata, Yoichiro Nakatani, Izumi Nagatomo, Satoshi Shiba, Yoshito Takeda, Yasushi Totoki, Sayaka Mizutani, Hironori Sunakawa, Hiroaki Ikematsu, Hiroyuki Takamaru, Atsushi Kumanogoh, Shinichi Yachida
A comprehensive endoscopic small and large intestinal untargeted step biopsy procedure was conducted to compare gene expression between the normal intestinal mucosa of healthy individuals and that of patients with colorectal tumors. From 78 participants (healthy individuals [n = 17], patients with colorectal conventional adenomas [n = 6], patients with Tis–T1 colorectal cancer [n = 41], patients with
-
SARS-CoV-2 nucleocapsid protein interaction with YBX1 displays oncolytic properties through PKM mRNA destabilization Mol. Cancer (IF 27.7) Pub Date : 2024-11-06 Xin Chen, Baohong Jiang, Yu Gu, Zhaoyang Yue, Ying Liu, Zhiwei Lei, Ge Yang, Minhua Deng, Xuelong Zhang, Zhen Luo, Yongkui Li, Qiwei Zhang, Xuepei Zhang, Jianguo Wu, Chunyu Huang, Pan Pan, Fangjian Zhou, Ning Wang
SARS-CoV-2, a highly contagious coronavirus, is responsible for the global pandemic of COVID-19 in 2019. Currently, it remains uncertain whether SARS-CoV-2 possesses oncogenic or oncolytic potential in influencing tumor progression. Therefore, it is important to evaluate the clinical and functional role of SARS-CoV-2 on tumor progression. Here, we integrated bioinformatic analysis of COVID-19 RNA-seq
-
A prospective multi-cohort study identifies and validates a 5-gene peripheral blood signature predictive of immunotherapy response in non-small cell lung cancer Mol. Cancer (IF 27.7) Pub Date : 2024-11-06 Shaoqiu Chen, Fangfang Liu, Yuanyuan Fu, Chris K. Deng, Jeffrey A. Borgia, Abdul-Ghani Ayman, Masaki Nasu, Mayumi Jijiwa, Hua Yang, Ting Gong, Junlong Wang, Zhougui Ling, Xiaoyan Wang, Hongwei Wang, Qian Chu, Youping Deng
Immune checkpoint inhibitors (ICIs) have revolutionized the treatment landscape for non-small cell lung cancer (NSCLC). The variability in patient responses necessitates a blood-based, multi-cohort gene signature to predict ICI response in NSCLC. We performed transcriptomic profiling of peripheral blood mononuclear cell (PBMC) and buffy coat (BC) samples from three independent cohorts of NSCLC patients
-
Nanoparticles and bone microenvironment: a comprehensive review for malignant bone tumor diagnosis and treatment Mol. Cancer (IF 27.7) Pub Date : 2024-11-01 Yujing Guan, Wei Zhang, Yuling Mao, Shenglong Li
Malignant bone tumors, which are difficult to treat with current clinical strategies, originate from bone tissues and can be classified into primary and secondary types. Due to the specificity of the bone microenvironment, the results of traditional means of treating bone tumors are often unsatisfactory, so there is an urgent need to develop new treatments for malignant bone tumors. Recently, nanoparticle-based
-
Folate-engineered chitosan nanoparticles: next-generation anticancer nanocarriers Mol. Cancer (IF 27.7) Pub Date : 2024-10-31 Prashant Kesharwani, Kratika Halwai, Saurav Kumar Jha, Mohammed H. AL Mughram, Salem Salman Almujri, Waleed H. Almalki, Amirhossein Sahebkar
Chitosan nanoparticles (NPs) are well-recognized as promising vehicles for delivering anticancer drugs due to their distinctive characteristics. They have the potential to enclose hydrophobic anticancer molecules, thereby enhancing their solubilities, permeabilities, and bioavailabilities; without the use of surfactant, i.e., through surfactant-free solubilization. This allows for higher drug concentrations
-
Cell-autonomous IL6ST activation suppresses prostate cancer development via STAT3/ARF/p53-driven senescence and confers an immune-active tumor microenvironment Mol. Cancer (IF 27.7) Pub Date : 2024-10-31 Christina Sternberg, Martin Raigel, Tanja Limberger, Karolína Trachtová, Michaela Schlederer, Desiree Lindner, Petra Kodajova, Jiaye Yang, Roman Ziegler, Jessica Kalla, Stefan Stoiber, Saptaswa Dey, Daniela Zwolanek, Heidi A. Neubauer, Monika Oberhuber, Torben Redmer, Václav Hejret, Boris Tichy, Martina Tomberger, Nora S. Harbusch, Jan Pencik, Simone Tangermann, Vojtech Bystry, Jenny L. Persson, Gerda
Prostate cancer ranks as the second most frequently diagnosed cancer in men worldwide. Recent research highlights the crucial roles IL6ST-mediated signaling pathways play in the development and progression of various cancers, particularly through hyperactivated STAT3 signaling. However, the molecular programs mediated by IL6ST/STAT3 in prostate cancer are poorly understood. To investigate the role
-
Overcoming multi-drug resistance in SCLC: a synergistic approach with venetoclax and hydroxychloroquine targeting the lncRNA LYPLAL1-DT/BCL2/BECN1 pathway Mol. Cancer (IF 27.7) Pub Date : 2024-10-31 Shuxin Li, Jianyi Lv, Zhihui Li, Qiuyu Zhang, Jing Lu, Xueyun Huo, Meng Guo, Xin Liu, Changlong Li, Jinghui Wang, Hanping Shi, Li Deng, Zhenwen Chen, Xiaoyan Du
Small cell lung cancer (SCLC) stands as one of the most lethal malignancies, characterized by a grim diagnosis and prognosis. The emergence of multi-drug resistance poses a significant hurdle to effective therapy. Although previous studies have implicated the long noncoding RNA LYPLAL1-DT in the tumorigenesis of SCLC, the precise role of the highly expressed LYPLAL1-DT in SCLC chemoresistance and the
-
Tumour-intrinsic PDL1 signals regulate the Chk2 DNA damage response in cancer cells and mediate resistance to Chk1 inhibitors Mol. Cancer (IF 27.7) Pub Date : 2024-10-30 Clare E. Murray, Anand V. R. Kornepati, Carlos Ontiveros, Yiji Liao, Bárbara de la Peña Avalos, Cody M. Rogers, Zexuan Liu, Yilun Deng, Haiyan Bai, Suresh Kari, Alvaro S. Padron, Jacob T. Boyd, Ryan Reyes, Curtis A. Clark, Robert S. Svatek, Rong Li, Yanfen Hu, Meiling Wang, José R. Conejo-Garcia, Lauren A. Byers, Kavya Ramkumar, Anil K. Sood, Jung-Min Lee, Christin E. Burd, Ratna K. Vadlamudi, Harshita
Aside from the canonical role of PDL1 as a tumour surface-expressed immune checkpoint molecule, tumour-intrinsic PDL1 signals regulate non-canonical immunopathological pathways mediating treatment resistance whose significance, mechanisms, and therapeutic targeting remain incompletely understood. Recent reports implicate tumour-intrinsic PDL1 signals in the DNA damage response (DDR), including promoting
-
Molecular mechanisms and therapeutic significance of Tryptophan Metabolism and signaling in cancer Mol. Cancer (IF 27.7) Pub Date : 2024-10-30 Jing Yan, Di Chen, Zi Ye, Xuqiang Zhu, Xueyuan Li, Henan Jiao, Mengjiao Duan, Chaoli Zhang, Jingliang Cheng, Lixia Xu, Hongjiang Li, Dongming Yan
Tryptophan (Trp) metabolism involves three primary pathways: the kynurenine (Kyn) pathway (KP), the 5-hydroxytryptamine (serotonin, 5-HT) pathway, and the indole pathway. Under normal physiological conditions, Trp metabolism plays crucial roles in regulating inflammation, immunity, and neuronal function. Key rate-limiting enzymes such as indoleamine-2,3-dioxygenase (IDO), Trp-2,3-dioxygenase (TDO)
-
Combined targeting of GPX4 and BCR-ABL tyrosine kinase selectively compromises BCR-ABL+ leukemia stem cells Mol. Cancer (IF 27.7) Pub Date : 2024-10-28 Chengwu Zeng, Dingrui Nie, Xianfeng Wang, Shuxin Zhong, Xiangbo Zeng, Xin Liu, Kangjie Qiu, Xueting Peng, Wenyi Zhang, Shengting Chen, Xianfeng Zha, Cunte Chen, Zhenhua Chen, Weizhang Wang, Yangqiu Li
In the ongoing battle against BCR-ABL+ leukemia, despite significant advances with tyrosine kinase inhibitors (TKIs), the persistent challenges of drug resistance and the enduring presence of leukemic stem cells (LSCs) remain formidable barriers to achieving a cure. In this study, we demonstrated that Disulfiram (DSF) induces ferroptosis to synergize with TKIs in inhibiting BCR-ABL+ cells, particularly
-
A multidimensional recommendation framework for identifying biological targets to aid the diagnosis and treatment of liver metastasis in patients with colorectal cancer Mol. Cancer (IF 27.7) Pub Date : 2024-10-24 Feng Qi, Na Gao, Jia Li, Chenfei Zhou, Jinling Jiang, Bin Zhou, Liting Guo, Xiaohui Feng, Jun Ji, Qu Cai, Liu Yang, Rongjia Zhu, Xinyi Que, Junwei Wu, Wenqi Xi, Wenxing Qin, Jun Zhang
The quest to understand the molecular mechanisms of tumour metastasis and identify pivotal biomarkers for cancer therapy is increasing in importance. Single-omics analyses, constrained by their focus on a single biological layer, cannot fully elucidate the complexities of tumour molecular profiles and can thus overlook crucial molecular targets. In response to this limitation, we developed a multiobjective
-
Epigenome-wide analysis across the development span of pediatric acute lymphoblastic leukemia: backtracking to birth Mol. Cancer (IF 27.7) Pub Date : 2024-10-23 Akram Ghantous, Semira Gonseth Nusslé, Farah J. Nassar, Natalia Spitz, Alexei Novoloaca, Olga Krali, Eric Nickels, Vincent Cahais, Cyrille Cuenin, Ritu Roy, Shaobo Li, Maxime Caron, Dilys Lam, Peter Daniel Fransquet, John Casement, Gordon Strathdee, Mark S. Pearce, Helen M. Hansen, Hwi-Ho Lee, Yong Sun Lee, Adam J. de Smith, Daniel Sinnett, Siri Eldevik Håberg, Jill A. McKay, Jessica Nordlund, Per
Cancer is the leading cause of disease-related mortality in children. Causes of leukemia, the most common form, are largely unknown. Growing evidence points to an origin in-utero, when global redistribution of DNA methylation occurs driving tissue differentiation. Epigenome-wide DNA methylation was profiled in surrogate (blood) and target (bone marrow) tissues at birth, diagnosis, remission and relapse
-
CAR-NK cells for gastrointestinal cancer immunotherapy: from bench to bedside Mol. Cancer (IF 27.7) Pub Date : 2024-10-23 Xingwang Zhu, Jieyun Xue, Hongzhou Jiang, Dongwei Xue
Gastrointestinal (GI) cancers represent a significant health burden worldwide. Their incidence continues to increase, and their management remains a clinical challenge. Chimeric antigen receptor (CAR) natural killer (NK) cells have emerged as a promising alternative to CAR-T cells for immunotherapy of GI cancers. Notably, CAR-NK cells offer several advantages, including reduced risk of graft-versus-host
-
Membrane-bound IL-7 immobilized by the CD8 transmembrane region improves efficacy of CD19 CAR-T cell therapy Mol. Cancer (IF 27.7) Pub Date : 2024-10-23 Chaoting Zhang, Ting Liu, Shance Li, Xia Teng, Yuge Zhu, Guanyu Zhang, Huimin Xie, Kang Sun, Jiaxin Tu, Wenjun Yang, Zheming Lu
Enhancing the efficacy of CD19 CAR-T cell therapy can significantly improve patient outcomes by reducing relapse rates in CD19 + B cell malignancies. Exogenous or transgenic cytokines are often used to boost the expansion and durability of CAR-T cells but pose risks of severe toxicities. A promising approach to address these limitations is to immobilize cytokines on the surface of CAR-T cells using
-
MicroRNAs are enriched at COVID-19 genomic risk regions, and their blood levels correlate with the COVID-19 prognosis of cancer patients infected by SARS-CoV-2 Mol. Cancer (IF 27.7) Pub Date : 2024-10-21 Simone Anfossi, Faezeh Darbaniyan, Joseph Quinlan, Steliana Calin, Masayoshi Shimizu, Meng Chen, Paola Rausseo, Michael Winters, Elena Bogatenkova, Kim-Anh Do, Ivan Martinez, Ziyi Li, Loredana Antal, Tudor Rares Olariu, Ignacio Wistuba, George A. Calin
Cancer patients are more susceptible to an aggressive course of COVID-19. Developing biomarkers identifying cancer patients at high risk of COVID-19-related death could help determine who needs early clinical intervention. The miRNAs hosted in the genomic regions associated with the risk of aggressive COVID-19 could represent potential biomarkers for clinical outcomes. Plasma samples were collected
-
Anti irradiation nanoparticles shelter immune organ from radio-damage via preventing the IKK/IκB/NF-κB activation Mol. Cancer (IF 27.7) Pub Date : 2024-10-19 Shigao Huang, Min Xu, Xiaojun Deng, Qingyue Da, Miaomiao Li, Hao Huang, Lina Zhao, Linlin Jing, Haibo Wang
Normal tissue and immune organ protection are critical parts of the tumor radiation therapy process. Radiation-induced immune organ damage (RIOD) causes several side reactions by increasing oxidative stress and inflammatory responses, resulting in unsatisfactory curability in tumor radiation therapy. The aim of this study was to develop a novel and efficient anti irradiation nanoparticle and explore
-
Correction: Identification of TRAIL-inducing compounds highlights small molecule ONC201/TIC10 as a unique anti-cancer agent that activates the TRAIL pathway Mol. Cancer (IF 27.7) Pub Date : 2024-10-18 Joshua E Allen, Gabriel Krigsfeld, Luv Patel, Patrick A Mayes, David T Dicker, Gen Sheng Wu, Wafik S El-Deiry
Correction: Mol Cancer 14, 99 (2015) https://doi.org/10.1186/s12943-015-0346-9 Following publication of the original article [1], the authors reported inadvertent errors in two panels of Figure 3. The original Figure 3B shows a duplication of a histological image. The duplicated image has been replaced and the images, as well as their labels, have been accurately arranged in the corrected Figure 3
-
R-loops’ m6A modification and its roles in cancers Mol. Cancer (IF 27.7) Pub Date : 2024-10-18 Yue Qiu, Changfeng Man, Luyu Zhu, Shiqi Zhang, Xiaoyan Wang, Dandan Gong, Yu Fan
R-loops are three-stranded nucleic acid structures composed of an RNA–DNA hybrid and a displaced DNA strand. They are widespread and play crucial roles in regulating gene expression, DNA replication, and DNA and histone modifications. However, their regulatory mechanisms remain unclear. As R-loop detection technology advances, changes in R-loop levels have been observed in cancer models, often associated
-
Correction: Acyl-coenzyme a binding protein (ACBP) - a risk factor for cancer diagnosis and an inhibitor of immunosurveillance Mol. Cancer (IF 27.7) Pub Date : 2024-10-17 Léa Montégut, Peng Liu, Liwei Zhao, María Pérez-Lanzón, Hui Chen, Misha Mao, Shuai Zhang, Lisa Derosa, Julie Le Naour, Flavia Lambertucci, Silvia Mingoia, Uxía Nogueira-Recalde, Rafael Mena-Osuna, Irene Herranz-Montoya, Nabil Djouder, Sylvain Baulande, Hui Pan, Adrien Joseph, Meriem Messaoudene, Bertrand Routy, Marine Fidelle, Tarek Ben Ahmed, Olivier Caron, Pierre Busson, David Boulate, Mélanie Deschasaux-Tanguy
Correction: Mol Cancer 23 187 (2024) https://doi.org/10.1186/s12943-024-02098-5 Following publication of the original article [1], the authors noticed a minor but significant error in the representation of the author name Tarek Ben Ahmed as “Ben” was captured as given name instead of a family name. Thus, in the online version, the name Tarek Ben Ahmed was mistakenly listed as Ahmed TB instead of Ben
-
Tumor-intrinsic role of ICAM-1 in driving metastatic progression of triple-negative breast cancer through direct interaction with EGFR Mol. Cancer (IF 27.7) Pub Date : 2024-10-16 Jae-Hyeok Kang, Nizam Uddin, Seungmo Kim, Yi Zhao, Ki-Chun Yoo, Min-Jung Kim, Sung-Ah Hong, Sangsu Bae, Jeong-Yeon Lee, Incheol Shin, Young Woo Jin, Heather M. O’Hagan, Joo Mi Yi, Su-Jae Lee
Triple-negative breast cancer (TNBC), the most aggressive subtype, presents a critical challenge due to the absence of approved targeted therapies. Hence, there is an urgent need to identify effective therapeutic targets for this condition. While epidermal growth factor receptor (EGFR) is prominently expressed in TNBC and recognized as a therapeutic target, anti-EGFR therapies have yet to gain approval
-
Prostate cancer microenvironment: multidimensional regulation of immune cells, vascular system, stromal cells, and microbiota Mol. Cancer (IF 27.7) Pub Date : 2024-10-12 Lin Chen, Yu-Xin Xu, Yuan-Shuo Wang, Ying-Ying Ren, Xue-Man Dong, Pu Wu, Tian Xie, Qi Zhang, Jian-Liang Zhou
Prostate cancer (PCa) is one of the most prevalent malignancies in males worldwide. Increasing research attention has focused on the PCa microenvironment, which plays a crucial role in tumor progression and therapy resistance. This review aims to provide a comprehensive overview of the key components of the PCa microenvironment, including immune cells, vascular systems, stromal cells, and microbiota
-
Size matters: integrating tumour volume and immune activation signatures predicts immunotherapy response Mol. Cancer (IF 27.7) Pub Date : 2024-10-11 Su Yin Lim, Ines Pires da Silva, Nurudeen A. Adegoke, Serigne N. Lo, Alexander M. Menzies, Matteo S. Carlino, Richard A. Scolyer, Georgina V. Long, Jenny H. Lee, Helen Rizos
Immune checkpoint inhibitors (ICIs) have transformed cancer treatment, providing significant benefit to patients across various tumour types, including melanoma. However, around 40% of melanoma patients do not benefit from ICI treatment, and accurately predicting ICI response remains challenging. We now describe a novel and simple approach that integrates immune-associated transcriptome signatures
-
Chaperone-mediated autophagy modulates Snail protein stability: implications for breast cancer metastasis Mol. Cancer (IF 27.7) Pub Date : 2024-10-11 Ki-Jun Ryu, Ki Won Lee, Seung-Ho Park, Taeyoung Kim, Keun-Seok Hong, Hyemin Kim, Minju Kim, Dong Woo Ok, Gu Neut Bom Kwon, Young-Jun Park, Hyuk-Kwon Kwon, Cheol Hwangbo, Kwang Dong Kim, J. Eugene Lee, Jiyun Yoo
Breast cancer remains a significant health concern, with triple-negative breast cancer (TNBC) being an aggressive subtype with poor prognosis. Epithelial-mesenchymal transition (EMT) is important in early-stage tumor to invasive malignancy progression. Snail, a central EMT component, is tightly regulated and may be subjected to proteasomal degradation. We report a novel proteasomal independent pathway
-
Advances and applications of RNA vaccines in tumor treatment Mol. Cancer (IF 27.7) Pub Date : 2024-10-09 Ruohan Yang, Jiuwei Cui
Compared to other types of tumor vaccines, RNA vaccines have emerged as promising alternatives to conventional vaccine therapy due to their high efficiency, rapid development capability, and potential for low-cost manufacturing and safe drug delivery. RNA vaccines mainly include mRNA, circular RNA (circRNA), and Self-amplifying mRNA(SAM). Different RNA vaccine platforms for different tumors have shown
-
Correction: RNA m6A modification in ferroptosis: implications for advancing tumor immunotherapy Mol. Cancer (IF 27.7) Pub Date : 2024-10-08 Jun-xiao Shi, Zhi-chao Zhang, Hao-zan Yin, Xian-jie Piao, Cheng-hu Liu, Qian-jia Liu, Jia-cheng Zhang, Wen-xuan Zhou, Fu-chen Liu, Fu Yang, Yue-fan Wang, Hui Liu
Correction: Mol Cancer 23, 213 (2024) https://doi.org/10.1186/s12943-024-02132-6 Following publication of the original article [1], the authors noticed that the Funding information was not indicated in the article. The details of Funding were included in the revised manuscript that was submitted by the author to production system. The Funding information is given below. The original article has been
-
Proapoptotic activity of JNK-sensitive BH3-only proteins underpins ovarian cancer response to replication checkpoint inhibitors Mol. Cancer (IF 27.7) Pub Date : 2024-10-07 Annapoorna Venkatachalam, Cristina Correia, Kevin L. Peterson, Xianon Hou, Paula A. Schneider, Annabella R. Strathman, Karen S. Flatten, Chance C. Sine, Emily A. Balczewski, Cordelia D. McGehee, Melissa C. Larson, Laura N. Duffield, X. Wei Meng, Nicole D. Vincelette, Husheng Ding, Ann L. Oberg, Fergus J. Couch, Elizabeth M. Swisher, Hu Li, S. John Weroha, Scott H. Kaufmann
Recent studies indicate that replication checkpoint modulators (RCMs) such as inhibitors of CHK1, ATR, and WEE1 have promising monotherapy activity in solid tumors, including platinum-resistant high grade serous ovarian cancer (HGSOC). However, clinical response rates are generally below 30%. While RCM-induced DNA damage has been extensively examined in preclinical and clinical studies, the link between
-
Artificial intelligence alphafold model for molecular biology and drug discovery: a machine-learning-driven informatics investigation Mol. Cancer (IF 27.7) Pub Date : 2024-10-05 Song-Bin Guo, Yuan Meng, Liteng Lin, Zhen-Zhong Zhou, Hai-Long Li, Xiao-Peng Tian, Wei-Juan Huang
AlphaFold model has reshaped biological research. However, vast unstructured data in the entire AlphaFold field requires further analysis to fully understand the current research landscape and guide future exploration. Thus, this scientometric analysis aimed to identify critical research clusters, track emerging trends, and highlight underexplored areas in this field by utilizing machine-learning-driven
-
Pharmacological targeting of P300/CBP reveals EWS::FLI1-mediated senescence evasion in Ewing sarcoma Mol. Cancer (IF 27.7) Pub Date : 2024-10-05 Erdong Wei, Ana Mitanoska, Quinn O’Brien, Kendall Porter, MacKenzie Molina, Haseeb Ahsan, Usuk Jung, Lauren Mills, Michael Kyba, Darko Bosnakovski
Ewing sarcoma (ES) poses a significant therapeutic challenge due to the difficulty in targeting its main oncodriver, EWS::FLI1. We show that pharmacological targeting of the EWS::FLI1 transcriptional complex via inhibition of P300/CBP drives a global transcriptional outcome similar to direct knockdown of EWS::FLI1, and furthermore yields prognostic risk factors for ES patient outcome. We find that
-
Deciphering resistance mechanisms in cancer: final report of MATCH-R study with a focus on molecular drivers and PDX development Mol. Cancer (IF 27.7) Pub Date : 2024-10-04 Damien Vasseur, Ludovic Bigot, Kristi Beshiri, Juan Flórez-Arango, Francesco Facchinetti, Antoine Hollebecque, Lambros Tselikas, Mihaela Aldea, Felix Blanc-Durand, Anas Gazzah, David Planchard, Ludovic Lacroix, Noémie Pata-Merci, Catline Nobre, Alice Da Silva, Claudio Nicotra, Maud Ngo-Camus, Floriane Braye, Sergey I. Nikolaev, Stefan Michiels, Gérôme Jules-Clement, Ken André Olaussen, Fabrice André
Understanding the resistance mechanisms of tumor is crucial for advancing cancer therapies. The prospective MATCH-R trial (NCT02517892), led by Gustave Roussy, aimed to characterize resistance mechanisms to cancer treatments through molecular analysis of fresh tumor biopsies. This report presents the genomic data analysis of the MATCH-R study conducted from 2015 to 2022 and focuses on targeted therapies
-
Correction: Nac1 promotes stemness and regulates myeloid‑derived cell status in triple‑negative breast cancer Mol. Cancer (IF 27.7) Pub Date : 2024-10-03 Chrispus Ngule, Ruyi Shi, Xingcong Ren, Hongyan Jia, Felix Oyelami, Dong Li, Younhee Park, Jinhwan Kim, Hami Hemati, Yi Zhang, Xiaofang Xiong, Andrew Shinkle, Nathan L. Vanderford, Sara Bachert, Binhua P. Zhou, Jianlong Wang, Jianxun Song, Xia Liu, Jin‑Ming Yang
Correction: Mol Cancer 23, 188 (2024) https://doi.org/10.1186/s12943-024-02102-y Following publication of the original article [1], the authors identified an error in Fig. 3 wherein the labeling of NAC1 and GAPDH blots were mistakenly swapped. The correct and incorrect figures are given below. Incorrect Figure 3: Correct Figure 3: Ngule C, Shi R, Ren X, et al. NAC1 promotes stemness and regulates myeloid-derived
-
Editorial expression of concern: miR-630 targets IGF1R to regulate response to HER-targeting drugs and overall cancer cell progression in HER2 over-expressing breast cancer Mol. Cancer (IF 27.7) Pub Date : 2024-10-01 Claire Corcoran, Sweta Rani, Susan Breslin, Martina Gogarty, Irene M Ghobrial, John Crown, Lorraine O’Driscoll
Correction:Mol Cancer 13, 71 (2014) https://doi.org/10.1186/1476-4598-13-71 Published: 24 March 2014 After the publication of this article, the publisher was alerted to an apparent panel duplication and frameshift in Fig. 4B migration (ii) SKBR3-LR NC mimic and 4 C invasion (ii) SKBR3-LR NC mimic. Because the issue was detected ten years after publication, the original images for the study are no longer
-
Traditional Chinese medicine for the treatment of cancers of hepatobiliary system: from clinical evidence to drug discovery Mol. Cancer (IF 27.7) Pub Date : 2024-10-01 Junyu Wu, Guoyi Tang, Chien-Shan Cheng, Ranna Yeerken, Yau-Tuen Chan, Zhiwen Fu, Yi-Chao Zheng, Yibin Feng, Ning Wang
Hepatic, biliary, and pancreatic cancer pose significant challenges in the field of digestive system diseases due to their highly malignant nature. Traditional Chinese medicine (TCM) has gained attention as a potential therapeutic approach with long-standing use in China and well-recognized clinical benefits. In this review, we systematically summarized the clinical applications of TCM that have shown
-
Chinese herbal medicine for the treatment of intestinal cancer: preclinical studies and potential clinical applications Mol. Cancer (IF 27.7) Pub Date : 2024-10-01 Juan Zhang, Yulin Wu, Yuanyang Tian, Hongxi Xu, Zhi-Xiu Lin, Yan-Fang Xian
Intestinal cancer (IC) poses a significant global health challenge that drives continuous efforts to explore effective treatment modalities. Conventional treatments for IC are effective, but are associated with several limitations and drawbacks. Chinese herbal medicine (CHM) plays an important role in the overall cancer prevention and therapeutic strategies. Recent years have seen a growing body of
-
Deciphering the role of LGALS2: insights into tertiary lymphoid structure-associated dendritic cell activation and immunotherapeutic potential in breast cancer patients Mol. Cancer (IF 27.7) Pub Date : 2024-09-30 Shuyu Li, Nan Zhang, Hao Zhang, Zhifang Yang, Quan Cheng, Kang Wei, Meng Zhou, Chenshen Huang
Recent advances in cancer research have highlighted the pivotal role of tertiary lymphoid structures (TLSs) in modulating immune responses, particularly in breast cancer (BRCA). Here, we performed an integrated analysis of bulk transcriptome data from over 6000 BRCA samples using biological network-based computational strategies and machine learning (ML) methods, and identified LGALS2 as a key marker
-
Sulindac (K-80003) with nab-paclitaxel and gemcitabine overcomes drug-resistant pancreatic cancer Mol. Cancer (IF 27.7) Pub Date : 2024-09-30 Cheng-Ke Xie, Cheng-Yu Liao, Hong-Yi Lin, Yong-Ding Wu, Feng-Chun Lu, Xiao-Xiao Huang, Zu-Wei Wang, Ge Li, Cai-Feng Lin, Jian-Fei Hu, Yin-Hao Chen, Qiao-Wei Li, Li-Qun Chen, Hui-Xing Chen, Shi Chen
The Nab-paclitaxel combined with gemcitabine (AG) regimen is the main chemotherapy regimen for pancreatic cancer, but drug resistance often occurs. Currently, the ability to promote sensitization in drug-resistant cases is an important clinical issue, and the strategy of repurposing conventional drugs is a promising strategy. This study aimed to identify a classic drug that targets chemotherapy resistance’s
-
CircRNA and lncRNA-encoded peptide in diseases, an update review Mol. Cancer (IF 27.7) Pub Date : 2024-09-30 Qian Yi, Jianguo Feng, Weiwu Lan, Houyin shi, Wei Sun, Weichao Sun
Non-coding RNAs (ncRNAs), including circular RNAs (circRNAs) and long non-coding RNAs (lncRNAs), are unique RNA molecules widely identified in the eukaryotic genome. Their dysregulation has been discovered and played key roles in the pathogenesis of numerous diseases, including various cancers. Previously considered devoid of protein-coding ability, recent research has revealed that a small number
-
RNA m6A modification in ferroptosis: implications for advancing tumor immunotherapy Mol. Cancer (IF 27.7) Pub Date : 2024-09-28 Jun-xiao Shi, Zhi-chao Zhang, Hao-zan Yin, Xian-jie Piao, Cheng-hu Liu, Qian-jia Liu, Jia-cheng Zhang, Wen-xuan Zhou, Fu-chen Liu, Fu Yang, Yue-fan Wang, Hui Liu
The pursuit of innovative therapeutic strategies in oncology remains imperative, given the persistent global impact of cancer as a leading cause of mortality. Immunotherapy is regarded as one of the most promising techniques for systemic cancer therapies among the several therapeutic options available. Nevertheless, limited immune response rates and immune resistance urge us on an augmentation for
-
The Technical University of Munich Cancer Center - elevating cancer treatment through science Mol. Cancer (IF 27.7) Pub Date : 2024-09-28 Judith S. Hecker, Hana Algül, Anna L. Illert, Florian Bassermann
The Technical University of Munich and the Ludwig Maximilian University Munich are both top-ranked universities on the national and international level and distinguished as “elite universities” within the national German Research Foundation (DFG)-funded excellence program. Both sites are established and leading cancer research institutions in Europe that have joined forces within the Comprehensive
-
Charting the metabolic biogeography of the colorectum in cancer: challenging the right sided versus left sided classification Mol. Cancer (IF 27.7) Pub Date : 2024-09-28 Abhishek Jain, Montana T. Morris, Domenica Berardi, Trisha Arora, Xavier Domingo-Almenara, Philip B. Paty, Nicholas J. W. Rattray, Daniel Kerekes, Lingeng Lu, Sajid A. Khan, Caroline H. Johnson
Colorectal cancer (CRC) is conventionally classified as right sided, left sided, and rectal cancer. Clinicopathological, molecular features and risk factors do not change abruptly along the colorectum, and variations exist even within the refined subsites, which may contribute to inconsistencies in the identification of clinically relevant CRC biomarkers. We generated a CRC metabolome map to describe
-
CD16+ as predictive marker for early relapse in aggressive B-NHL/DLBCL patients Mol. Cancer (IF 27.7) Pub Date : 2024-09-28 Sylvia Zöphel, Nadja Küchler, Johanna Jansky, Cora Hoxha, Gertrud Schäfer, Julius J. Weise, Joanne Vialle, Lea Kaschek, Gebhard Stopper, Hermann Eichler, Daniela Yildiz, Alina Moter, Philipp Wendel, Evelyn Ullrich, Claudia Schormann, Torben Rixecker, Onur Cetin, Frank Neumann, Patrick Orth, Moritz Bewarder, Markus Hoth, Lorenz Thurner, Eva C. Schwarz
Assessing the prognosis of patients with aggressive non-Hodgkin B cell lymphoma mainly relies on a clinical risk score (IPI). Standard first-line therapies are based on a chemo-immunotherapy with rituximab, which mediates CD16-dependent antibody-dependent cellular cytotoxicity (ADCC). We phenotypically and functionally analyzed blood samples from 46 patients focusing on CD16+ NK cells, CD16+ T cells
-
PBA2, a novel inhibitor of the β-catenin/CBP pathway, eradicates chronic myeloid leukemia including BCR-ABL T315I mutation Mol. Cancer (IF 27.7) Pub Date : 2024-09-28 Ke Yang, Kai Fu, Hong Zhang, Xiaokun Wang, Kenneth K.W. To, Caibo Yang, Fang Wang, Zhe-Sheng Chen, Liwu Fu
BCR-ABL is a constitutively active tyrosine kinase that stimulates multiple downstream signaling pathways to promote the survival and proliferation of chronic myeloid leukemia (CML) cells. The clinical application of specific BCR-ABL tyrosine kinase inhibitors (TKIs) has led to significantly improved prognosis and overall survival in CML patients compared to previous treatment regimens. However, direct
-
CircLIFRSA/miR-1305/PTEN axis attenuates malignant cellular processes in non-small cell lung cancer by regulating AKT phosphorylation Mol. Cancer (IF 27.7) Pub Date : 2024-09-28 Meina Jiang, Huihui Bai, Shuai Fang, Chengwei Zhou, Weiyu Shen, Zhaohui Gong
Non-small cell lung cancer (NSCLC) is typically diagnosed at advanced stages, which limits the effectiveness of therapeutic interventions. The present study aimed to explore the role of the newly identified circLIFRSA in the PTEN/AKT signaling pathway and its involvement in the malignant processes of NSCLC. CircLIFRSA expression was identified through microarray analysis, and its levels in NSCLC samples
-
Circular RNA-encoded oncogenic PIAS1 variant blocks immunogenic ferroptosis by modulating the balance between SUMOylation and phosphorylation of STAT1 Mol. Cancer (IF 27.7) Pub Date : 2024-09-28 Xin Zang, Xiao-Yu He, Cheng-Mei Xiao, Qing Lin, Meng-Yue Wang, Cheng-Yan Liu, Ling-Yi Kong, Zhong Chen, Yuan-Zheng Xia
The clinical response rate to immune checkpoint blockade (ICB) therapy in melanoma remains low, despite its widespread use. Circular non-coding RNAs (circRNAs) are known to play a crucial role in cancer progression and may be a key factor limiting the effectiveness of ICB treatment. The circRNAs that were downregulated after coadministration compared with single administration of PD-1 inhibitor administration
-
A high proportion of germline variants in pediatric chronic myeloid leukemia Mol. Cancer (IF 27.7) Pub Date : 2024-09-26 Manuela Krumbholz, Anna Dolnik, Eric Sträng, Tabita Ghete, Sabrina Skambraks, Stephan Hutter, Alfred Simonis, Frank Stegelmann, Meinolf Suttorp, Anselm H.C. Horn, Heinrich Sticht, Torsten Haferlach, Lars Bullinger, Markus Metzler
Chronic myeloid leukemia (CML) typically occurs in late adulthood. Pediatric CML is a rare form of leukemia. In all age groups, the characteristic genetic driver of the disease is the BCR::ABL1 fusion gene. However, additional genomic events contribute to leukemic transformation, which is not yet well-characterized in pediatric CML. We investigated the mutational landscape of pediatric CML to determine
-
FTO-mediated DSP m6A demethylation promotes an aggressive subtype of growth hormone-secreting pituitary neuroendocrine tumors Mol. Cancer (IF 27.7) Pub Date : 2024-09-20 Yunzhi Zou, Xiaoqiong Bao, Depei Li, Zhen Ye, Rong Xiang, Yuanzhong Yang, Zhe Zhu, Ziming Chen, Lingxing Zeng, Chunling Xue, Hongzhe Zhao, Boyuan Yao, Qilin Zhang, Zeming Yan, Zekun Deng, Jintong Cheng, Guanghao Yue, Wanming Hu, Jixiang Zhao, Ruihong Bai, Zhenhua Zhang, Aiqun Liu, Jialiang Zhang, Zhixiang Zuo, Xiaobing Jiang
Growth hormone-secreting pituitary neuroendocrine tumors can be pathologically classified into densely granulated (DGGH) and sparsely granulated types (SGGH). SGGH is more aggressive and associated with a poorer prognosis. While epigenetic regulation is vital in tumorigenesis and progression, the role of N6-methyladenosine (m6A) in aggressive behavior has yet to be elucidated. We performed m6A-sequencing
-
Developmental interplay between transcriptional alterations and a targetable cytokine signaling dependency in pediatric ETO2::GLIS2 leukemia Mol. Cancer (IF 27.7) Pub Date : 2024-09-20 Verónica Alonso-Pérez, Klaudia Galant, Fabien Boudia, Elie Robert, Zakia Aid, Laurent Renou, Vilma Barroca, Saryiami Devanand, Loélia Babin, Virginie Rouiller-Fabre, Delphine Moison, Didier Busso, Guillaume Piton, Christophe Metereau, Nassera Abermil, Paola Ballerini, Pierre Hirsch, Rima Haddad, Jelena Martinovic, Arnaud Petit, Hélène Lapillonne, Erika Brunet, Thomas Mercher, Françoise Pflumio
Several fusion oncogenes showing a higher incidence in pediatric acute myeloid leukemia (AML) are associated with heterogeneous megakaryoblastic and other myeloid features. Here we addressed how developmental mechanisms influence human leukemogenesis by ETO2::GLIS2, associated with dismal prognosis. We created novel ETO2::GLIS2 models of leukemogenesis through lentiviral transduction and CRISPR-Cas9
-
Altered metabolism in cancer: insights into energy pathways and therapeutic targets Mol. Cancer (IF 27.7) Pub Date : 2024-09-18 Muhammad Tufail, Can-Hua Jiang, Ning Li
Cancer cells undergo significant metabolic reprogramming to support their rapid growth and survival. This study examines important metabolic pathways like glycolysis, oxidative phosphorylation, glutaminolysis, and lipid metabolism, focusing on how they are regulated and their contributions to the development of tumors. The interplay between oncogenes, tumor suppressors, epigenetic modifications, and
-
Spatiotemporal metabolomic approaches to the cancer-immunity panorama: a methodological perspective Mol. Cancer (IF 27.7) Pub Date : 2024-09-18 Yang Xiao, Yongsheng Li, Huakan Zhao
Metabolic reprogramming drives the development of an immunosuppressive tumor microenvironment (TME) through various pathways, contributing to cancer progression and reducing the effectiveness of anticancer immunotherapy. However, our understanding of the metabolic landscape within the tumor-immune context has been limited by conventional metabolic measurements, which have not provided comprehensive
-
Unraveling the extracellular vesicle network: insights into ovarian cancer metastasis and chemoresistance Mol. Cancer (IF 27.7) Pub Date : 2024-09-16 Wei Dai, Jianwei Zhou, Ting Chen
Ovarian cancer (OC) is one of the most prevalent and lethal gynecological malignancies, with high mortality primarily due to its aggressive nature, frequent metastasis, and resistance to standard therapies. Recent research has highlighted the critical role of extracellular vesicles (EVs) in these processes. EVs, secreted by living organisms and carrying versatile and bioactive cargoes, play a vital